Interstitial Lung Disease Induced by Monoclonal Antibodies for Psoriatic Arthritis, a Double Hit: A Case Report with a Literature and Clinical Trial Review. [PDF]
Castelli G +11 more
europepmc +1 more source
Efficacy of Secukinumab in Chinese Patients with Moderate-to-Severe Hidradenitis Suppurativa: A 16-Week, Single-Center, Prospective, Real-World Study. [PDF]
Wu C +5 more
europepmc +1 more source
Secukinumab in Refractory Generalized Darier's Disease with a 40-Year Disease Duration: A Case Report. [PDF]
Ou Y, Fang H, Liu T, Cai Z, Cheng L.
europepmc +1 more source
Integrating Patient-Centric Clinical Pharmacology and MID3 to Advance Biologic Development in Immune-Mediated Inflammatory Diseases. [PDF]
Ait-Oudhia S +3 more
europepmc +1 more source
Real-World Effectiveness of Secukinumab in Congenital Ichthyoses: A Retrospective Monocentric Case Series. [PDF]
Crespi O +8 more
europepmc +1 more source
Case Report: Successful treatment of new onset plaque psoriasis with secukinumab in a peritoneal dialysis patient. [PDF]
Fang J, Li R, Xie Y, Liu Y.
europepmc +1 more source
Probable paradoxical pyoderma gangrenosum associated with secukinumab in a patient with severe plaque psoriasis. [PDF]
Genevcius CF +4 more
europepmc +1 more source
IL-17 ligand-targeting inhibitors in psoriatic arthritis: a focused systematic review and network meta-analysis of efficacy, safety, and certainty of evidence. [PDF]
AbuJwaid YK +12 more
europepmc +1 more source
Adverse events associated with candida infections in secukinumab treatment. [PDF]
Yu C, Ma T, Wu N, Li C, Wang R.
europepmc +1 more source
Application of IL-17A Inhibitors in Psoriasis Complicated by Multiple Infections - Successful Treatment and Insights from a Case of Psoriasis with HIV and Neurosyphilis. [PDF]
Mao TT, Yu FF, Ma P, Qi ML.
europepmc +1 more source

